{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:57:55Z","timestamp":1760547475669,"version":"3.41.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1023\/a:1020566218512","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T20:12:43Z","timestamp":1048018363000},"page":"145-156","source":"Crossref","is-referenced-by-count":2,"title":["A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer"],"prefix":"10.1007","volume":"76","author":[{"given":"Leisha A.","family":"Emens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. John","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Fetting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5094986_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1\u201315, 71\u201385, 1992","journal-title":"Lancet"},{"key":"5094986_CR2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1200\/JCO.1994.12.8.1621","volume":"12","author":"WH Wilson","year":"1994","unstructured":"Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'shaughnessy J, Balis F, Chabner B: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I\/II trial of 96-hour infusion. J Clin Oncol 12: 1621\u20131629, 1994","journal-title":"J Clin Oncol"},{"key":"5094986_CR3","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1200\/JCO.1986.4.8.1162","volume":"4","author":"W Hryniuk","year":"1986","unstructured":"Hryniuk W, Levine MN: Analysis of dose intensity for ad-juvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162\u20131170, 1986","journal-title":"J Clin Oncol"},{"key":"5094986_CR4","first-page":"1","volume":"35","author":"H Skipper","year":"1964","unstructured":"Skipper H, Schatel FJ, Wilcox W: Experimental evaluation of potential anticancer agents XIII: on the criteria and kinetics associated with curability of experimental leukemias. Cancer Chemother Rep 35: 1, 1964 (abstract)","journal-title":"Cancer Chemother Rep"},{"key":"5094986_CR5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jnci\/92.3.225","volume":"92","author":"G Hortobagyi","year":"2000","unstructured":"Hortobagyi G, Busdar A, Theriault R, Valero V, Frye E, Booser D: Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast cancer. J Natl Canc Inst 92: 225\u2013233, 2000","journal-title":"J Natl Canc Inst"},{"key":"5094986_CR6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(98)01350-6","volume":"352","author":"S Rodenhuis","year":"1998","unstructured":"Rodenhuis S, Richel DJ, van der Wall E, Schornagel J, Baars L, Koning C, Peterse J, Borger J, Nooijian W, Bakx R, Dalesio O, Rutgers E: Randomized trial of high-dose chemo-therapy and hematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515\u2013521, 1998","journal-title":"Lancet"},{"key":"5094986_CR7","first-page":"1a","volume":"18","author":"WP Peters","year":"1999","unstructured":"Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L for CALGB: A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer in-volving ten or more axillary lymph nodes: preliminary results of CALGB 9082\/SWOG 9114\/NCIC MA-13. Proc Am Soc Clin Oncol 18: 1a, 1999 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5094986_CR8","first-page":"2a","volume":"18","author":"Scandinavian Breast Cancer Study Group 9401.","year":"1999","unstructured":"Scandinavian Breast Cancer Study Group 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone mar-row stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 18: 2a, 1999 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5094986_CR9","first-page":"28a","volume":"19","author":"S Rodenhuis","year":"2000","unstructured":"Rodenhuis S, Bontenbal M, Beex L, van der Wall E, Richel D, Mooij M, Voest E, Hupperets P, Westermann A, Dalesio O, deVries E: Randomized phase III study of high-dose chemo-therapy with cyclophosphamide, thiotepa, and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc Am Soc Clin Oncol 19: 28a, 2000 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5094986_CR10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00282-999-0071-1","volume":"41","author":"JP Lotz","year":"1999","unstructured":"Lotz JP, Cure H, Janvier M, Morvan F, Legros M, Asselain B, Guillemo M, Roche H, Gisselbrecht C: Intensive chemother-apy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the National Protocol Pegase 04. Hematol Cell Ther 41: 71\u201374, 1999","journal-title":"Hematol Cell Ther"},{"key":"5094986_CR11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJM200004133421501","volume":"342","author":"EA Stadtmauer","year":"2000","unstructured":"Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH: Conventional-dose chemotherapy com-pared with high-dose chemotherapy plus autologous hema-topoietic stem-cell transplantation for metastatic breast cancer. Philadelphia bone marrow transplant group. N Engl J Med 342: 1069\u20131076, 2000","journal-title":"N Engl J Med"},{"key":"5094986_CR12","first-page":"7067","volume":"48","author":"L Norton","year":"1988","unstructured":"Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48: 7067\u20137071, 1988","journal-title":"Cancer Res"},{"key":"5094986_CR13","first-page":"769","volume-title":"Cancer Medicine","author":"A Surbone","year":"1996","unstructured":"Surbone A, Gilewski T, Norton L: Cytokinetics. In: Holland JF, Frei III E, Bast Jr RC, Morton DL, Kufe DW, Weichselbaum RR (eds) Cancer Medicine. Vol 1, 4th edn. Williams & Wilkins, Baltimore, MD, 1996, pp 769\u2013798","edition":"4th edn."},{"key":"5094986_CR14","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","volume":"83","author":"FA Holmes","year":"1991","unstructured":"Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: A phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797\u20131805, 1991","journal-title":"J Natl Cancer Inst"},{"key":"5094986_CR15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.1999.17.1.93","volume":"17","author":"C Hudis","year":"1999","unstructured":"Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moy M, Sklarin N, Fennelly D, Crown JP, Surbone A, Ulenhopp M, Riedel E, Yao TJ, Norton L: Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for respectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 17: 93\u2013100, 1999","journal-title":"J Clin Oncol"},{"key":"5094986_CR16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jnci\/82.7.582","volume":"82","author":"DH Kern","year":"1990","unstructured":"Kern DH, Weisenthal LM: Highly specific prediction of an-tineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82: 582\u2013588, 1990","journal-title":"J Natl Cancer Inst"},{"key":"5094986_CR17","first-page":"640","volume":"26","author":"PM Hoff","year":"1999","unstructured":"Hoff PM, Royce M, Medgyesy D, Brito R, Pazdur R: Oral fluoropyrimidines. Semin Oncol 26: 640\u2013646, 1999","journal-title":"Semin Oncol"},{"key":"5094986_CR18","first-page":"52","volume":"26","author":"P Hoff","year":"1999","unstructured":"Hoff P, Pazdur R: Dihydropyrimidine dehydrogenase inhib-itory fluoropyrimidines: a novel class of oral antineoplastic agents. Semin Oncol 26(suppl 18): 52\u201356, 1999","journal-title":"Semin Oncol"},{"key":"5094986_CR19","first-page":"26","volume":"13","author":"CG Leichman","year":"1999","unstructured":"Leichman CG: Schedule dependency of 5-fluorouracil. Onco-logy, 13(suppl 3): 26\u201332, 1999","journal-title":"Onco-logy"},{"key":"5094986_CR20","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.1991.9.11.2027","volume":"9","author":"DL Trump","year":"1991","unstructured":"Trump DL, Egorin M, Forrest A, Wilson JKV, Remick S, Tutsch KD: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9: 2027\u20132035, 1991","journal-title":"J Clin Oncol"},{"key":"5094986_CR21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","volume":"352","author":"Early Breast Cancer Trialist's Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialist's Collaborative Group: Poly-chemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930\u2013942, 1998","journal-title":"Lancet"},{"key":"5094986_CR22","first-page":"101a","volume":"17","author":"IC Henderson","year":"1998","unstructured":"Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle JN, Cooper MR, Canellos G, Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of pa-tients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17: 101a, 1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5094986_CR23","first-page":"1073","volume":"8","author":"AU Buzdar","year":"2002","unstructured":"Buzdar AU, Singletar SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau S-W, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN: Evaluation of paclitaxel in adjuvant chemo-therapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Canc Res 8: 1073\u20131079, 2002","journal-title":"Clin Canc Res"},{"key":"5094986_CR24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","volume":"273","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna G, Zambetti M, Valagussa P: Sequential or alter-nating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273: 542\u2013547, 1995","journal-title":"JAMA"},{"key":"5094986_CR25","first-page":"3934","volume":"7","author":"MN Fornier","year":"2001","unstructured":"Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski R, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C: Doxorubi-cin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Canc Res 7: 3934\u20133941, 2001.","journal-title":"Clin Canc Res"},{"key":"5094986_CR26","first-page":"36a","volume":"21","author":"CM Haskell","year":"2002","unstructured":"Haskell CM, Green SJ, Sledge GW, Shapiro CL, Ingle JN, Lew D, Martino S, Livingston RB, Osborne CK for SWOG, ECOG, and CALGB: Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A \u00a8C) in breast cancer patients with 0\u20133 positive nodes (Intergroup 0137). Proc Am Soc Clin Oncol 21: 36a, 2002 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5094986_CR27","first-page":"35a","volume":"21","author":"MC Green","year":"2002","unstructured":"Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales M, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault R, Carter C, Singletary SE, Kuerer HM, Hunt K, Strom E, Hortobagyi GN: Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week paclitaxel therapy followed by FAC \u2013 final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 21: 35a, 2002 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5094986_CR28","first-page":"34a","volume":"21","author":"M Untch","year":"2002","unstructured":"Untch M, Konecny G, Ditsch N, Sorokina Y, Moebus V, Muck B, Kuhn W, Bastert G, Werner C, Thomssen C, Wallwiener D, Albert U, Bothmann G, Kreienberg R, Luck HJ: Dose dense sequential epirubicin\u2013paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol 21: 34a, 2002 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"5094986_CR29","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreatico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxor-ubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688\u20132699, 1995","journal-title":"J Clin Oncol"},{"key":"5094986_CR30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","volume":"7","author":"J Gehl","year":"1996","unstructured":"Gehl J, Boesgaard M, Paaske T, Jensen BV, Dombernowsky P: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7: 687\u2013793, 1996","journal-title":"Ann Oncol"},{"key":"5094986_CR31","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.1997.15.5.1906","volume":"15","author":"L Gianni","year":"1997","unstructured":"Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906\u20131915, 1997","journal-title":"J Clin Oncol"},{"key":"5094986_CR32","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1200\/JCO.1996.14.10.2713","volume":"14","author":"FA Holmes","year":"1996","unstructured":"Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Rooser DG, Buzdar AU, Willey J, Hortobagyi GN: Sequence-dependent alteration of doxor-ubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713\u20132721, 1996","journal-title":"J Clin Oncol"},{"key":"5094986_CR33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/86.2.143","volume":"86","author":"SL Berg","year":"1994","unstructured":"Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, Poplack DG, O'shaughnessy JA: Pharmacokinetics of taxol and doxorubicin administered alone and in combin-ation by continuous 72-hour infusion. J Natl Cancer Inst 86: 143\u2013145, 1994","journal-title":"J Natl Cancer Inst"},{"key":"5094986_CR34","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1476-5381.1993.tb13909.x","volume":"110","author":"PS Mushlin","year":"1993","unstructured":"Mushlin PS, Cusack BJ, Boucek Jr RJ, Andrejuk T, Li X, Olson RD: Time-related increases in cardiac concentra-tions of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110: 975\u2013982, 1993","journal-title":"Br J Pharmacol"},{"key":"5094986_CR35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/bjc.1996.90","volume":"73","author":"LK Webster","year":"1996","unstructured":"Webster LK, Cosson EJ, Stokes KH, Millward MD: Effect of the paclitaxel vehicle, cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73: 522\u2013524, 1996","journal-title":"Br J Cancer"},{"key":"5094986_CR36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2001.26434","volume":"28","author":"V Valero","year":"2001","unstructured":"Valero V, Perez E, Dieras V: Doxorubicin and taxane combin-ation regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol 28: 15\u201323, 2001","journal-title":"Semin Oncol"},{"key":"5094986_CR37","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/j.1552-4604.1993.tb01943.x","volume":"33","author":"DL Keefe","year":"1993","unstructured":"Keefe DL, Roistacher N, Pierri MK: Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharm 33: 1060\u20131070, 1993","journal-title":"J Clin Pharm"},{"key":"5094986_CR38","first-page":"374","volume":"28","author":"AJ Anand","year":"1994","unstructured":"Anand AJ: Fluorouracil cardiotoxicity. Ann Pharm 28: 374\u2013378, 1994","journal-title":"Ann Pharm"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020566218512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1020566218512\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1020566218512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020566218512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:27:44Z","timestamp":1750480064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1020566218512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["5094986"],"URL":"https:\/\/doi.org\/10.1023\/a:1020566218512","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}